Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

Gabriel Etienne, MD, PHD, Nicolini E Nicolini, MD, PhD, Stéphanie Dulucq, Anna Schmitt, Sandrine Hayette, Éric Lippert, MD, PhD, Isabelle Tigaud, MD, Stephane Morisset, Stat., Caroline Bureau, Didier Adiko, Gerald Marit, MD, Josy Reiffers, MD, Francois-Xavier Mahon, MD, PhD

Blood (2012) 120 (21): 3754.

https://doi.org/10.1182/blood.V120.21.3754.3754

Published: 2012

Journal Articles

Cbl Controls the Expression of Axl and Lyn Tyrosine Kinases Mediating Resistance to Nilotinib in Chronic Myeloid Leukemia Cells

Claire Tregoat, Romain Gioia, Ph.D, Valérie Lagarde, Valerie Prouzet-Mauleon, Éric Lippert, MD, PhD, Audrey Sirvent, Serge Roche, Ph, D, Francois-Xavier Mahon, MD, PhD, Jean-Max Pasquet

Blood (2012) 120 (21): 3734.

https://doi.org/10.1182/blood.V120.21.3734.3734

Published: 2012

Journal Articles

Interlaboratory Quality Control Round of MPL Mutation Detection in Fourteen European Laboratories: A MPN&MPNr-EuroNet Study,

Naomi A. Porret, PhD, Elisabeth Oppliger Leibundgut, PharmD, Serge Carillo, Bruno Cassinat, PharmD, Francois Girodon, MD, PhD, Éric Lippert, MD, PhD, Valérie Ugo, MD, PhD, Sylvie Hermouet, MD, PhD, Paola Guglielmelli, MD, Jiri Schwarz, MD, PhD, Beatriz Bellosillo, Susanne Schnittger, PhD, Maj K. Westman, Stephane Giraudier, MD, PhD

Blood (2011) 118 (21): 3859.

https://doi.org/10.1182/blood.V118.21.3859.3859

Published: 2011

Journal Articles

Induced Pluripotent Stem Cells (iPSC) From Chronic Myeloid Leukemia: Study of BCR-ABL Addiction and Effect of Tyrosine Kinase Inhibitors,

Aurélie Bedel, Sr., Pharm D, PhD, Francois Moreau-Gaudry, MD, PhD, Jean- Max Pasquet, Sr., PhD, Miguel Taillepierre, Éric Lippert, MD, PhD, Valérie Lagarde, Hubert de Verneuil, MD, PhD, Emmanuel Richard, PhD, Francois-Xavier Mahon, MD, PhD

Blood (2011) 118 (21): 3754.

https://doi.org/10.1182/blood.V118.21.3754.3754

Published: 2011

Journal Articles

Potent Graft-Versus-Leukemia Effect After Reduced Intensity (RIC) Allogeneic Stem-Cell Transplantation (ASCT) As Post-Remission Therapy for Intermediate-Risk De-Novo Acute Myeloid Leukemia (AML) with FLT3-ITD Genotype or Wild-Type (WT) NPM1 and CEBPA without FLT3-ITD,

Gaëlle Labouré, Stephanie Dulucq, MD, Stephane Vigouroux, MD, Éric Lippert, MD, PhD, Arnaud Pigneux, MD, PhD, Reza Tabrizi, MD, Thibaut Leguay, MD, Krimo Bouabdallah, MD, Marie-Sarah Dilhuydy, MD, Anna Schmitt, Gerald Marit, MD, PhD, Francois-Xavier Mahon, MD, PhD, Noel Milpied, MD

Blood (2011) 118 (21): 4129.

https://doi.org/10.1182/blood.V118.21.4129.4129

Published: 2011

Journal Articles

Surface Expression of Mpl: Aberrant Mpl Trafficking In Myeloproliferative Neoplasms Is Linked to Insufficient Expression of Wild Type Jak2

Cédric Cleyrat, PhD, Mathias Vilaine, Marjorie Boissinot, PhD, Francois Girodon, MD, PhD, Mara P. Steinkamp, PhD, Irène Dobo, MD, Éric Lippert, MD, PhD, Isabelle Corre, PhD, Bridget S. Wilson, PhD, Sylvie Hermouet, MD, PhD

Blood (2011) 118 (21): 2820.

https://doi.org/10.1182/blood.V118.21.2820.2820

Published: 2011

NARROW

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

Cbl Controls the Expression of Axl and Lyn Tyrosine Kinases Mediating Resistance to Nilotinib in Chronic Myeloid Leukemia Cells

Interlaboratory Quality Control Round of MPL Mutation Detection in Fourteen European Laboratories: A MPN&MPNr-EuroNet Study,

Induced Pluripotent Stem Cells (iPSC) From Chronic Myeloid Leukemia: Study of BCR-ABL Addiction and Effect of Tyrosine Kinase Inhibitors,

Potent Graft-Versus-Leukemia Effect After Reduced Intensity (RIC) Allogeneic Stem-Cell Transplantation (ASCT) As Post-Remission Therapy for Intermediate-Risk De-Novo Acute Myeloid Leukemia (AML) with FLT3-ITD Genotype or Wild-Type (WT) NPM1 and CEBPA without FLT3-ITD,

Surface Expression of Mpl: Aberrant Mpl Trafficking In Myeloproliferative Neoplasms Is Linked to Insufficient Expression of Wild Type Jak2

Email alerts

ASH Publications

American Society of Hematology

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

Cbl Controls the Expression of Axl and Lyn Tyrosine Kinases Mediating Resistance to Nilotinib in Chronic Myeloid Leukemia Cells

Interlaboratory Quality Control Round of MPL Mutation Detection in Fourteen European Laboratories: A MPN&MPNr-EuroNet Study,

Induced Pluripotent Stem Cells (iPSC) From Chronic Myeloid Leukemia: Study of BCR-ABL Addiction and Effect of Tyrosine Kinase Inhibitors,

Potent Graft-Versus-Leukemia Effect After Reduced Intensity (RIC) Allogeneic Stem-Cell Transplantation (ASCT) As Post-Remission Therapy for Intermediate-Risk De-Novo Acute Myeloid Leukemia (AML) with FLT3-ITD Genotype or Wild-Type (WT) NPM1 and CEBPA without FLT3-ITD,

Surface Expression of Mpl: Aberrant Mpl Trafficking In Myeloproliferative Neoplasms Is Linked to Insufficient Expression of Wild Type Jak2

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only